ArticleAmerican journal of hematology2026

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Matteo Molica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.